Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Erasca, Inc.NASDAQ: ERAS
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $47.2M rose 110.0% year over year, ahead of the +39.6% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +110.0% holds above the trailing-twelve-month pace of +39.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 92.85M USD
- Year-over-year change
- -19.5%
- 4-year CAGR
- +5.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.85M | -19.5% |
| FY2024 | 2024-12-31 | 115.36M | +11.1% |
| FY2023 | 2023-12-31 | 103.82M | -7.7% |
| FY2022 | 2022-12-31 | 112.46M | +52.1% |
| FY2021 | 2021-12-31 | 73.92M | — |
Research & Development vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 research & development of $133.6M is the 5th highest of the 9 companies compared; the peer median is $141.08M.
- Its year-over-year change of +39.6% is the 2nd highest of 9, against a peer median of +16.3%.
- Over three fiscal years its annual growth of -6.2% compares with a peer median of +35.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Sep 2026 | $133.6M | +39.6% | -6.2% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| Peer median (excluding ERAS) | $141.08M | +16.3% | +35.3% | 200.1% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 829K | 2.64M | 3.73M | 0 | 3.11M |
| Gross Profit | (829K) | (2.64M) | (3.73M) | 0 | (3.11M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M |
| Selling, General & Admin | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M |
| Operating Expenses | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| EBITDA | (121.94M) | (240.16M) | (121.31M) | (153.28M) | (121.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (124.88M) | (247.45M) | (141.53M) | (179.59M) | (131.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 190K | 4.9M | 16.71M | 20.09M | 16.61M |
| Interest Expense | 0 | 201.36M | 0 | 0 | 0 |
| Other Income / Expenses | 2.12M | 4.65M | 16.48M | 17.94M | 6.86M |
| Income Before Tax | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| EPS (Diluted) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| Weighted Avg Shares | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
| Weighted Avg Shares (Diluted) | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.